2024

• Differential requirements for Smarca5 expression during hematopoietic stem cell commitment. Turkova T, Kokavec J, Zikmund T, Dibus N, Pimkova K, Nemec D, Holeckova M, Ruskova L, Sedlacek R, Cermak L, Stopka T.Commun Biol. 2024 Feb 29;7(1):244. doi: 10.1038/s42003-024-05917-z. (IF 5.9) [PubMed] 

2023

• Chromatin Remodeling Enzyme Snf2h Is Essential for Retinal Cell Proliferation and Photoreceptor Maintenance. Kuzelova A, Dupacova N, Antosova B, Sunny SS, Kozmik Z Jr., Paces J, Skoultchi AI, Stopka T, Kozmik Z.  Cells. 2023; 12(7):1035. https://doi.org/10.3390/cells12071035 (IF 7.67) [PubMeb]

• SILAC-IodoTMT for Assessment of the Cellular Proteome and Its Redox Status. Vajrychova M, Salovska B, Pimkova K, Fabrik I, Hodny Z. Methods Mol Biol. 2023;2603:259-268. doi: 10.1007/978-1-0716-2863-8_21. [PubMed]
  

2022

• G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Stopka T, Minarik L, Dusilkova N, Pesta M, Kulvait V, Spacek M, Zemanova Z, Kalousova M, and Jonasova A. Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2. (IF 11.98) [PubMed] 

• Quantitative analysis of redox proteome reveals oxidation-sensitive protein thiols acting in fundamental processes of developmental hematopoiesis. Pimkova K, Jassinskaja M, Munita R, Ciesla M, Guzzi N, Cao Thi Ngoc P, Vajrychova M, Johansson E, Bellodi C, Hansson J. Redox Biology. Volume 53, July 2022, 102343. ISSN 2213-2317. https://doi.org/10.1016/j.redox.2022.102343. (IF 11.79) [PubMed]

• Peroxiredoxin 6 protects irradiated cells from oxidative stress and shapes their senescence-associated cytokine landscape.Salovska B, Kondelova A, Pimkova K, Liblova Z, Pribyl M, Fabrik I, Bartek J, Vajrychova M, Hodny Z.  Redox Biol. 2022 Feb;49:102212. doi: 10.1016/j.redox.2021.102212. (IF 10.79) [PubMed]
  

• Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. Bašová P, Paszeková H, Minařík L, Dluhošová M, Burda P, Stopka T. International Journal of Molecular Sciences. 2022; 23(12):6729. https://doi.org/10.3390/ijms23126729. (IF 5.9) [PubMed] 

• Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. Krsmanovic P, Mocikova H, Chramostova K, Klanova M, Trnkova M, Pesta M, Laslo P, Pytlik R, Stopka T, Trneny M, Pospisil V. Cancers. 2022; 14(9):2305. https://doi.org/10.3390/cancers14092305 (IF 6.6) [PubMed]

• Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization. Thakur S, Cahais V, Turkova T, Zikmund T, Renard C, Stopka T, Korenjak M, Zavadil J. Cells 2022, 11,808. https://doi.org/10.3390/cells11050808 (IF 6.6) [PubMed]

• Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Cells. 2022; 11(2):223. https://doi.org/10.3390/cells11020223. (IF 6.6) [PubMed]

2021

• Co se ví o doplňcích stravy u MDS aneb proč má smysl se zabývat komplementární terapií? Tomáš Stopka. Myelodysplastic Syndrome NEWS. ISSN 2336-1093    Ročník 9 / číslo 1 / duben 2020. (131)
  
  
• Mutace u pacientů s MDS a jejich využití pro klinickou praxi. Tomáš Stopka. Myelodysplastic Syndrome NEWS. ISSN 2336-1093 Ročník 9 / číslo 2 / listopad 2021. (131)

2020

• Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T, Jonasova A, Bokorova R, Fuchs O, Stritesky J, Salovska B, Bartek J, Hodny Z. [published online ahead of print, 2020 Jul 21]. Mol Oncol. 2020;10.1002/1878-0261.12768. doi:10.1002/1878-0261.12768. (IF 6.574) [PubMed]
   
• Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. Zikmund T, Paszekova H, Kokavec J, Kerbs P, Thakur S, Turkova T, Tauchmanova P, Greif PA, Stopka T. Int J Mol Sci. 2020;21(6):E2073. Published 2020 Mar 18. doi:10.3390/ijms21062073. (IF 4.183) [PubMed]
 
• The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi AI, Zhang Y.  Genes Dev. 2020 Jan 9. doi: 10.1101/gad.331157.119. (IF 8.998) [PubMed]
 
• Universal promoter scanning by Pol II during transcription initiation in Saccharomyces cerevisiae. Qiu C, Jin H, Vvedenskaya I, Llenas JA, Zhao T, Malik I, Visbisky AM, Schwartz SL, Cui P, Čabart P, Han KH, Lai W, Metz RP, Johnson CD, Sze SH, Pugh BF, Nickels BE & Kaplan, CD (2020). Genome biology, 21(1), 132. https://doi.org/10.1186/s13059-020-02040-0. (IF 14.028)[PubMed] 

• Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry. Minarik L, Vargova K, Dusilkova N, Kulvait V, Jonasova A, Kodet O, Stopka T. Folia Biol (Praha). 2020;66(1):1-6. (IF 1.073) [PubMed] (H, 131)

2019

• ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing b-selection. Zikmund T, Kokavec J, Turkova T, Savvulidi P, Paszekova H, Vodenkova S, Sedlacek R, Skoultchi AI, and Stopka T. Journal of Immunology. J Immunol. 2019 Jun 15;202(12):3434-3446. doi: 10.4049/jimmunol.1801684.(IF 4.539) [PubMed]

• Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty.Skalicka P, Dudakova L, Palos M, Huna L, Evans CJ, Mahelkova G, Meliska M, Stopka T, Tuft S, Liskova P. Acta Ophthalmologica. Acta Ophthalmol. 2019 May 2. doi: 10.1111/aos.14123. (IF 3.032) [PubMed]

• Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS. Minarik L, Zemanova Z, Kulvait V, Dluhosova M, Jonasova A and Stopka T. Ann Hematol Oncol. 2019; 6(1): 0000.(IF 2.219)[PDF]  
 
• Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika – interim analýza. Stopka T, Minařík Ĺ, Kulvait V, Pešta M, Schaffartziková A, Kislik G, Dusílková N, Zemanová Z, Jonášová A. Myelodysplastic Syndrome News. Listopad 2019. Ročník 7 / číslo 2. [PDF]
  

2018

• BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086. (IF 9.9) [PubMed] (I, 131)

• Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin±prednisone addition to lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, Michalova K, Zemanova Z. Leukemia Research 69 (2018) 12-17. 2018 March 27. https://doi.org/10.1016/j.leukres.2018.03.015 . (IF 2.501) [PDF] (H, 131)
   
• 1. interim analýza randomizované otevřené klinické studie GA-MDS/2013. Dusilkova N, Minarik L, Stopka T, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 6 / Číslo 1 / květen 2018. [PDF] (N, 131)
  

2017

• Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selectin in patients-responders. Polgarova K, Vargova K, Kulvait V, Dusilkova N, Minarik L, Zemanova Z, Pesta M, Jonasova A and Stopka T. Oncotarget. 2017 Dec 6. (IF 5.168) [PDF] (B, N, H, 131)
   
• Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas. Dusilkova N, Basova P, Polivka J, Kodet O, Kulvait V, Pesta M, Trneny M, Stopka T. Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136. (IF: 3.226) [PDF]
   
• Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer.Basova P, Pesta M, Sochor M, Stopka T. Int J Mol Sci. 2017 Oct 10;18(10). pii: E2116. doi: 10.3390/ijms18102116(IF: 3.226) [PDF]
   
• Kokavec J, Zikmund T, Savvulidi F, Kulvait V, Edelmann W, Skoultchi AI, Stopka T. The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. Stem Cells. 2017 Jun;35(6):1614-1623. doi: 10.1002/stem.2604. (IF: 5.599) [PubMed]
   
• Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.215. (IF: 7.519)[PDF]
   
• Využití detekce somatických mutací pro pacienty s cytopenií nejasného významu a u myelodysplastického syndromu. Stopka T. Myelodysplastic Syndrome NEWS. Ročník 5 / Číslo 1 / květen 2017. [PDF]
   
• Vargova K, Pesta M, Obrtlíkova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M and Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. (IF: 6.126) [PDF]
  

2016

• DN Papageorgiou, E Karkoulia, A Amaral-Psarris, P Burda, K Kolodziej, JA Demmers, J Bungert, T Stopka, J Strouboulis. Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: evidence for co-repressor functions. Biochim Biophys Acta. 2016 Dec;1859(12):1515-1526. doi: 10.1016/j.bbagrm.2016.09.007. (IF: 5.373) [PubMed]
   
• J. Vargova, K. Vargova, N.Dusilkova, V. Kulvait, V. Pospisil, J. Zavadil, M. Trneny, P. Klener, and T. Stopka. Differential Expression, Localization and Activity of MARCKS between Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. Blood Cancer J. 2016 Sep 23;6(9):e475. (IF: 6.126) [PDF]
   
• He S, Limi S, McGreal RS, Xie Q, Brennan LA, Kantorow WL, Kokavec J, Majumdar R, Hou H Jr, Edelmann W, Liu W, Ashery-Padan R, Zavadil J, Kantorow M, Skoultchi AI, Stopka T, Cvekl A. Chromatin remodeling enzyme Snf2h regulates embryonic lens differentiation and denucleation. Development. 2016 Jun 1;143(11):1937-47. doi: 10.1242/dev.135285. (IF 6.462) [PDF]
   
• P Burda, J. Vargova, N Curik, C Salek, G Papadopoulos, J Strouboulis and T. Stopka. GATA-1 inhibits PU.1 gene via DNA and histone H3K9 Methylation of its Distal Enhancer in Erythroleukemia. PLoS One, 2016 Mar 24;11(3):e0152234 (IF 3.234)[PDF]
  

2015

• H. Huskova, K. Korecka, J. Karban, K. Vargova, J. Vargova, N. Dusilkova, M. Trneny, and T. Stopka. Oncogenic microRNA-155 and its target PU.1: An integrative gene expression study in six of the most prevalent lymphomas. International Journal of Hematology, Int J Hematol. 2015 Oct;102(4):441-50. (IF 1.918) [PubMed]
   
• K. Machova Polakova, V. Kulvait, Adela Benesova,J. Linhartova, H. Klamova, M. Jaruskova, C. de Benedittis, T. Haferlach, M. Baccarani, G. Martinelli, T. Stopka, T. Ernst, A. Hochhaus, A. Kohlmann, and S. Soverini. Next generation deep-sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol.2015 May;141(5):887-99. (IF 3.141)[PubMed]
  

2014

• A. Laslo P* and Stopka T*.Transcriptional and epigenetic regulation in the development of myeloid cells: normal and diseased myelopoiesis. Book Chapter, 2014. “Epigenetics and Human Health” publisher: Springer*Equal Corresponding Author, in press 2013,  issued Feb2014
   
• Dluhosova M, Curik N, Vargova J, Jonasova A, Zikmund T,Stopka T.Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5. PLoS One. 2014 Feb 3;9(2):e87448. (IF 3.534) [PDF]
   
• Alvarez-Saavedra M, De Repentigny Y, Lagali PS, Raghu Ram EV, Yan K, Hashem E, Ivanochko D, Huh MS, Yang D, Mears AJ, Todd MA, Corcoran CP, Bassett EA, Tokarew NJ, Kokavec J, Majumder R, Ioshikhes I, Wallace VA, Kothary R, Meshorer E, Stopka T, Skoultchi AI, Picketts DJ. Snf2h-mediated chromatin organization and histone H1 dynamics govern cerebellar morphogenesis and neural maturation. Nat Commun. 2014 Jun 20;5:4181 (IF 11.470) [PDF]
   
• Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V, Stopka T. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014 Jun 18;14:448.(IF 3.362) [PDF]
   
• Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L, Dluhosova M, Kuzmova E, Jonasova A, Steidl U, Laslo P, Stopka T. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 2014 Sep 25;33(39):4735-45. doi: 10.1038/onc.2013.414. (IF 8.459) [PubMed]
  

2013

• Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36. doi: 10.1007/s11899-012-0152-z. (IF 2.3) [PDF]
   
• N Curik, P Burda, K Vargova, V Pospisil, M Belickova, P Vlckova, F Savvulidi, E Necas, H Hajkova, C Haskovec, J Cermak, M Krivjanska, M Trneny, P Laslo, A Jonasova and T Stopka. 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia, 2012 Aug;26(8):1804-11.(IF 9.51) [PubMed]
   
• Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlikova P, Karban J, Mraz M, Pospisilova S, Mayer J, Trneny M, Zavadil J, Stopka T. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011 Apr 7;117(14):3816-25. (IF 10.5) [PubMed]
   
• Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A, Necas E, Zavadil J, Laslo P, andStopka T. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J. 2011 Sep 6. (IF 10.1) [PubMed]
   
• Machová Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T, Moravcová J. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011 Apr 18;10:41. doi: 10.1186/1476-4598-10-41. (IF 3.78) [PubMed]
  

2010

• Burda P., Laslo P. and Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 2010, 1-9.(IF 8.3) [PubMed]
   
• Michael Papetti, Sandeep N. Wontakal, Tomas Stopka and Arthur I. Skoultchi. GATA-1 directly regulates p21 gene expression during erythroid differentiation. Cell Cycle 9:10, 1-9; May 15, 2010.(IF 4.1) [PubMed]
  

2009

• Vargova J, Vargova K, and Stopka T. Nuclear Localization of Chromatin Remodeling ISWI ATPase Smarca5 (Snf2h) in Mouse. Front Biosci. E1, 553-559, June 1, 2009 (IF 3.308) [PubMed]
   
• Burda P, Curik N, Kokavec J, Basova P, Mikulenkova D, Skoultchi AI, Zavadil J and Stopka T. PU.1 Activation Relieves GATA-1–Mediated Repression of Cebpa and Cbfb during Leukemia Differentiation. Mol Cancer Res 2009, 7(10): OF1-11.(IF 4.533) [PubMed]
   
• Kokavec J, Vargova J, Burda P, Vargova K, Necas E, Zavadil J, and Stopka T. SWI/SNF2 proteins in germinal and early embryonic development. Folia Zool. – 58 (Suppl. 1): (2009). (IF 0.522)
  

2008

• Kokavec J, Podskocova J, Zavadil J, Stopka T. Chromatin remodeling and SWI/SNF2 factors in human disease. Front Biosci. 2008 May 1;13:6126-34 (IF 2.989) [PubMed]